R&D

Endocyte again changes terms of public offering

February 4, 2011
 IBJ Staff and Bloomberg News
The West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more than previously announced, but at a lower price of $6 each.
More

Potential competitor to Lilly drug shows promise in study

February 2, 2011
 IBJ Staff and Bloomberg News
Sanofi-Aventis's experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.'s twice-daily medicine Byetta, a study found.
More

21st Century Fund pockets a payoff from saleRestricted Content

January 22, 2011
Chris O'Malley
The state’s principal fund investing in high-tech companies has reached a milestone—for the first time recouping all the money it granted an emerging company, and then some.
More

Carmel firm gets FDA approval for lice treatment

January 18, 2011
 IBJ Staff
ParaPRO LLC's treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
More

Lilly partner moves up timetable for diabetes drug

January 11, 2011
Bloomberg News
Amylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable and submit a heart-safety study to regulators by the end of 2011, its CEO said.
More

Lilly, other big drugmakers shut out by FDA in 2010

January 3, 2011
 IBJ Staff and Bloomberg News
Regulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer Inc., the world's largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same time, according to agency records.
More

Roche acquires Marcadia Biotech

December 30, 2010
Chris O'Malley
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
More

Indiana Seed Fund makes 11th investment

December 23, 2010
 IBJ Staff
A $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development stage.
More

Lilly suspends late-stage trial for melanoma drug

December 13, 2010
Bloomberg News
Eli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study died.
More

Lilly, Acrux receive FDA approval for Axiron

November 24, 2010
 IBJ Staff and Bloomberg News
The companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year in the United States.
More

Study: Arthritis drug co-developed by Lilly shows promise

November 12, 2010
 IBJ Staff and Bloomberg News
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
More

Acquisition big step for Lilly Diagnostics

November 10, 2010
J.K. Wall
Eli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s attempt to add diagnostics to its product portfolio.
More

Drugmaker restarts race to boost 'good' cholesterol

November 10, 2010
Bloomberg News
Merck & Co. is betting it can succeed where Pfizer Inc. failed, with a new type of drug to combat heart disease by raising good cholesterol levels. Indianapolis-based Eli Lilly and Co. is testing a similar pill.
More

Lilly to open diabetes research center in China

November 2, 2010
 IBJ Staff
Indianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing the high incidence of the disease there.
More

Eli Lilly will have to beat odds to meet drug-rollout goals

October 30, 2010
J.K. Wall
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
More

UPDATE: Lilly, others see stock slide after drug rejection

October 20, 2010
Bloomberg News
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
More

Consultants: Pharma industry facing huge changes

October 6, 2010
J.K. Wall
Heitzman_WatchVideoTo date, most analysts say health reform turned out pretty well for the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen over the past three decades.
More

CEO says Lilly still not interested in huge acquisitions

September 7, 2010
 IBJ Staff and Bloomberg News
Lilly remains disinterested in making big acquisitions and aims to rely on the company’s own pipeline, CEO John Lechleiter said Tuesday, re-emphasizing a strategy he has outlined several times in the past year.
More

Lilly wins ban of generic Strattera pending appeal

August 31, 2010
Bloomberg News
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until the court rules on a judge's decision invalidating a patent on the medicine.
More

Endocyte's $86M IPO plan a boon for Indiana, investors

August 28, 2010
Greg Andrews
Venture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital, Clarian Health Ventures and the Indiana Future Fund.
More

Lilly wins further delay in sales of Strattera copies

August 26, 2010
Bloomberg News
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would translate into an average $1.22 million in sales.
More

Lilly gains panel's backing to expand Cymbalta use

August 19, 2010
Bloomberg News
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis of studies in lower back pain and osteoarthritis of the knee.
More

Lilly Alzheimer's drug prospect only the latest to fail

August 18, 2010
Bloomberg News
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the disease since 1906, have failed in mid- to late-stage testing since 2003.
More

Lilly's Cymbalta helps chronic pain in U.S. review

August 17, 2010
Bloomberg News
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta's annual sales.
More

Lilly braces for plunge in profits

August 14, 2010
J.K. Wall
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of loss of revenue that it's hard to picture what the company will look like in five years.
More
Page  << 1 2 3 4 5 6 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Uh, sorry Johnnie, but you are incorrect. Despite the assertions by yourself and various defenders and captains, sports attendance is NOT off significantly at most sporting events in the US. Variances in attendance has been in the range of single digits, both + & - for years now. MLB has had most of its best overall attendance nubers in the last decade, and that trend has been consistent for most major sporting events. The number one issue cited by most fans when asked about attendance is the overall cost of attending. The presence of HD and big screen televisions in home doesn't even register, as a factor for not attending an event. VALUE in the product is the key, and apparently is something lacking in the current ICS. What other explanation is there when with what is routinely touted as the "best" racing on the planet, fans are staying away in DROVES. A "close" title battle into the last event at Fontana, with the "cars and stars" of the ICS, and who showed up? MAYBE 8K. Sorry, but HD TV isn't to blame for that kind of fan apathy.

  2. Do you need finance to establish your business ? Are you interested in getting a loan at 3% from our private company? If so please Email: suntrust_oil@blumail.org

  3. If she was worth the $ the public outcry over direct tv dropping them would have kept them on their dishes as we have seen with other companies. I too quit watching channel 13 after she showed up since I left channel 8 because of her all show rather than production results. When Randy on 8 corrected her she had a big head and incorrectly challenged his correction for pronunciation of a city. Other antics while she matures was too much for me with her very inaccurate forecasts. All the forecasters were predicting rain until Thursday except Chris. They predicted sunny on Thursday but instead of rain until Thursday upon which the sun would finally make it out in full glory Chris was right on the money just as I too predicted looking at the radar on weather.gov. One thing I love about Angela is the fear you can see in her every time it thunders in the winter. It far exceeds the entertainment value of her body language (high heel noise drags, depression, etc) when her forecasts are so incorrect. Her hair stands on end, you have to see it!!!

  4. Good Day, Apply For A Loan I am Mr Fernadez Antonio, a private Loan lender and a cooperate financial for real estate and any kinds of business financing. I also offer Loans to individuals, Firms and cooperate bodies at 3% interest rate We offer any kind of loans. email us via fernadezloaninvest@outlook.com LOAN APPLICATION FORM First name:......................... Middle name:......................... Last name:........................................ Date of birth (yyyy-mm-dd):....................... Gender:........................................... Marital status:................................... Total Amount Needed............................... Loan Duration.................................... Address:.......................................... City:............................................. State/province:................................... Zip/postal code:.................................. Country:.......................................... Phone:............................................ Fax:.............................................. Mobile/cellular:.................................. Monthly Income.................................... Occupation:....................................... Best Regard, Mr Fernadez Antonio.

  5. i will love to share my testimony to you all the people in world i got married to my husband about 2 year ago we start having problems at home like we stop sleeping on the same bed,fighting about little things he always comes home late at night,drinking too much and sleeping with other women out side i have never love any man in my life except him. he is the father of my child and i don't want to loose him because we have worked so hard together to become what we are and have today .few month ago he now decided to live me and the kid,being a single mother can be hard sometimes and so i have nobody to turn to and i was heart broken.i called my mom and explain every thing to her,my mother told me about DR.okoro how he helped her solve the problem between her and my dad i was surprise about it because they have been without each other for three and a half years and it was like a miracle how they came back to each other. i was directed to DR. okoro on his email:okorospell@gmail.com and explain everything to him,so he promise me not to worry that he will cast a spell and make things come back to how we where so much in love again and that it was another female spirit that was controlling my husband he told me that my problem will be solved within two days if i believe i said OK So he cast a spell for me and after two days my love came back asking me to forgive him i Am so happy now. so that why i decided to share my experience with every body that have such problem contact Dr okoro the great spell caster on his email addresses spellcasterforlove@outlook.com

ADVERTISEMENT